Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for
Possible Violations of Federal Securities Laws
NEW YORK, Nov. 13, 2013
NEW YORK, Nov. 13, 2013 /PRNewswire/ --Levi & Korsinsky is investigating
Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NasdaqGM: SRPT) for
possible breaches of fiduciary duty.
(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )
Click here to learn more about the investigation:
http://zlk.9nl.com/sarepta-srpt/or call: 877-363-5972. There is no cost or
obligation to you.
On November 11, 2013, the Company announced that it had been instructed by the
Food and Drug Administration not to file for accelerated approval of
eteplirsen, the Company's drug to treat Duchenne muscular dystrophy. Sarepta
shares fell more than 64% upon this news.
If you own Sarepta stock and wish to obtain additional information about the
investigation and your legal rights, please contact Joseph E. Levi, Esq.
either via email at email@example.com or by telephone at (212) 363-7500,
toll-free: (877) 363-5972, or visit http://zlk.9nl.com/sarepta-srpt/.
Levi & Korsinsky is a national firm with offices in New York, New Jersey,
Connecticut and Washington D.C. The firm's 26 attorneys have extensive
expertise in prosecuting securities litigation involving financial fraud,
representing investors throughout the nation in securities and shareholder
lawsuits. For more information, please feel free to contact any of the
attorneys listed below. Attorney advertising. Prior results do not guarantee
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
SOURCE Levi & Korsinsky, LLP
Press spacebar to pause and continue. Press esc to stop.